Psyence Biomedical (PBM) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Quoin Pharmaceuticals (QNRX) has outperformed Psyence Biomedical (PBM) over the past year, losing 82.1% versus a loss of 94.9%. Psyence Biomedical is the larger company by market cap ($15.8 million vs $15.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBM | QNRX |
|---|---|---|
| Share price | $2.97 | $3.28 |
| Market cap | $15.80M | $15.76M |
| 1-day change | +3.85% | -2.35% |
| YTD return | -89.90% | -77.27% |
| 1-year return | -94.90% | -82.07% |
| 5-year return | — | -99.99% |
| P/E ratio (TTM) | — | 7.45 |
| EPS (TTM) | $-12.56 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.01M | $-15.80M |
| 52-week high | $73.44 | $23.50 |
| 52-week low | $1.92 | $3.18 |
| Distance from 52-week high | -95.96% | -86.04% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +565.55% |
| Average volume | 61.93K | 541.26K |
| Shares outstanding | 5.32M | 4.80M |
| Employees | 12 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QNRX has outperformed PBM by 12.8 percentage points over the past year.
About Psyence Biomedical
PBM stock →Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
PBM vs QNRX FAQ
Which is bigger, Psyence Biomedical or Quoin Pharmaceuticals?
Psyence Biomedical (PBM) is larger, with a market capitalization of $15.80M compared with $15.76M for Quoin Pharmaceuticals (QNRX).
Which stock has performed better over the past year, PBM or QNRX?
QNRX returned -82.07% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.
Are Psyence Biomedical and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.